In the next seven years around 640 million euros will be invested in Galvani Bioelectronics, if the company manages to achieve good academic results.
The company, which is named after the eighteenth-century Italian scientist Luigi Galvani, conducts research into “bio-electronic medication.”
Galvani wants to produce nerve signals can change or develop tiny implantable devices. According to GSK could be addressed include chronic diseases such as diabetes, arthritis and asthma using bioelectronics.
The new company will be 55 percent owned by GSK and 45 percent of Alphabet component Verily , the former Google Life Sciences. Research will be used by the UK facilities of GSK in Stevenage. In addition, a research location in San Francisco.
The company expects to receive approval within seven years of the regulator for the use of implantable devices.
No comments:
Post a Comment